Trial Profile
An extension study for patients with Hodgkin's disease or non-Hodgkin's lymphoma previously treated with SGN-30 (anti-CD30 mAb)
Status:
Not stated
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 22 Jun 2007
Price :
$35
*
At a glance
- Drugs SGN 30 (Primary)
- Indications Hodgkin's disease; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 22 Jun 2007 New trial record.